Join FP2020 by Making a Commitment

Pfizer commits to selling Sayana® Press for US$1/dose to qualified purchasers for two years. Sayana® Press combines Depo-Provera with Uniject™, a completely self-contained one-dose injection system that eliminates the need for health workers to store medicines and syringes or measure out doses. The price agreement allows Sayana® Press to be offered to women in FP2020 countries at reduced or zero cost. Financial support is provided by the Bill & Melinda Gates Foundation (BMGF) and Children’s Investment Fund Foundation (CIFF), while in-country distribution is made possible by PATH, DFID, UNFPA, and USAID. 

Pfizer is responsible for quality manufacturing of Sayana® Press, as well as obtaining registrations in key markets. Sayana® Press has been registered or has registration pending in over 10 of the 69 priority family planning markets. In addition, stakeholders have sought waivers to make Sayana® Press available in markets where there is no registration.

The consortium of public and private sector donors and aid organizations supporting this collaboration will assist with procurement and support country introductions and the delivery of Sayana® Press to health facilities. At the country level, the organizations will also work with local governments to help ensure injectable contraceptive methods are included in reproductive health plans and budgets, coordinate health worker trainings, and raise awareness about the availability of Sayana® Press.